2nd Wnt/β-Catenin Pathway Targeted Drug Development Summit

With an improved understanding of biology and mechanisms of action, the Wnt/β-Catenin community is surging through the clinic in 2022 with positive clinical updates. The excitement of a potential first-in-class candidate to advent combination, immuno-oncology therapies in colorectal, head & neck and non-small cell lung cancer is offering hope for patients with high unmet medical needs.

After 2 decades of research, we are excited to see milestones reached within drug developers, including Tonix Pharmaceuticals targeting Wnt/ β-catenin pathway as a broad-spectrum antiviral strategy, Boehringer Ingelheim/Surrozen collaboration seeking retinal therapies along the Wnt pathway. It is now the time for drug developers to act and get together at the 2nd Wnt/β-Catenin Pathway Targeted Drug Development Summit. As the one and only industry-led meeting, you will be equipped with unparalleled insights in:

  • Wnt/β-Catenin’s structural biology and medicinal chemistry – turning the undruggable druggable
  • Comparison of different Wnt/β-Catenin modulation approaches, its interaction with TIL and tumor microenvironment for targeted, combination therapies
  • Translating basic science into the clinical design – from scheduling to dosing, overcoming toxicity to widen the therapeutic window with safety in mind
  • Validating a clinical biomarker for patient selection